Cue Biopharma (CUE) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Cue Biopharma stock (CUE) is currently trading at $0.25. Cue Biopharma PS ratio (Price-to-Sales) is 0.94. Analyst consensus price target for CUE is $4.00. WallStSmart rates CUE as Sell.
- CUE PE ratio analysis and historical PE chart
- CUE PS ratio (Price-to-Sales) history and trend
- CUE intrinsic value — DCF, Graham Number, EPV models
- CUE stock price prediction 2025 2026 2027 2028 2029 2030
- CUE fair value vs current price
- CUE insider transactions and insider buying
- Is CUE undervalued or overvalued?
- Cue Biopharma financial analysis — revenue, earnings, cash flow
- CUE Piotroski F-Score and Altman Z-Score
- CUE analyst price target and Smart Rating
Cue Biopharma
📊 No data available
Try selecting a different time range
Smart Analysis
Cue Biopharma (CUE) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales, price/book, revenue growth. Concerns around market cap and return on equity. Mixed signals suggest waiting for clearer direction before acting.
Cue Biopharma (CUE) Key Strengths (3)
Paying less than $1 for every $1 of annual revenue
Trading below book value, meaning the market prices it less than net assets
Revenue surging 1292.00% year-over-year
Supporting Valuation Data
Cue Biopharma (CUE) Areas to Watch (5)
Company is destroying shareholder value
Company is losing money with a negative profit margin
Very thin margins with limited operational efficiency
Micro-cap company with very limited liquidity and high volatility
Low institutional interest, mostly retail-driven
Cue Biopharma (CUE) Detailed Analysis Report
Overall Assessment
This company scores 42/100 in our Smart Analysis, earning a D grade. Out of 8 metrics analyzed, 3 register as strengths (avg 10.0/10) while 5 fall into concern territory (avg 1.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Sales, Price/Book, Revenue Growth. Valuation metrics including Price/Sales (0.94), Price/Book (0.95) suggest the stock is attractively priced. Growth metrics are encouraging with Revenue Growth at 1292.00%.
The Bear Case
The primary concerns are Return on Equity, Profit Margin, Operating Margin. Profitability pressure is visible in Return on Equity at -121.10%, Operating Margin at 8.92%, Profit Margin at -96.90%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -121.10% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 1292.00% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Profit Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
CUE Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
CUE's Price-to-Sales ratio of 0.94x trades at a deep discount to its historical average of 234.21x (1th percentile). The current valuation is 100% below its historical high of 1395x set in Dec 2019, and 7% above its historical low of 0.88x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~9.0x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Cue Biopharma (CUE) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Cue Biopharma is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 27M with 1292% growth year-over-year. The company is currently unprofitable, posting a -96.9% profit margin.
Key Findings
Revenue growing at 1292% YoY, reaching 27M. This pace significantly outperforms most BIOTECHNOLOGY peers.
Spending 60% of revenue (17M) on R&D, reinforcing its commitment to innovation and future growth.
The company is unprofitable with a -96.9% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -1M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Cue Biopharma maintain 1292%+ revenue growth, or will competition slow it down?
Volatility is elevated with a beta of 1.55, so expect amplified moves relative to the broader market.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Cue Biopharma.
Bottom Line
Cue Biopharma is a high-conviction growth story with revenue accelerating at 1292% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin -96.9% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Cue Biopharma(CUE)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biological drugs for the selective modulation of the human immune system to treat a variety of cancers, chronic infectious diseases, and autoimmune disorders. The company is headquartered in Cambridge, Massachusetts.